North America Pharmaceutical CDMO Industry on Track to Achieve $105.42 Billion

North America Pharmaceutical Contract Development and Manufacturing Market Set to Reach $105.42 Billion by 2030

North America Pharmaceutical Contract Development and Manufacturing Market - 2024-2030 Meticulous Research , a leading global market research company, published a research report titled, 'North America Pharmaceutical Contract Development and Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma] - Forecast to 2030. Download Free Sample Report@ https://www.meticulousresearch.com/download-sample- report/cp_id=5749?utm_source=pdf&utm_medium=social&utm_campaign=product&utm_co ntent=24-09-2024 According to the latest report from Meticulous Research , the North America pharmaceutical contract development and manufacturing market is projected to reach $105.42 billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030. The market's expansion is driven by factors such as the increasing prevalence of chronic diseases, rising health awareness, a growing elderly population, and heightened pharmaceutical R&D spending. Additional drivers include low-cost manufacturing benefits, increasing government support for drug research, and improvements in healthcare infrastructure and spending. However, a shortage of skilled professionals presents a challenge to market growth. Opportunities are emerging from the rising demand for personalized medicine, cell and gene therapies, and the growth of high-potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC). Key Players Major players in the North American pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific Inc. (U.S.), Catalent, Inc. (U.S.), C.H. Boehringer Sohn AG & Co. KG (Germany), Synoes Health, Inc. (U.S.), Curia Global, Inc. (U.S.), Cambrex Corporation (U.S.), FUJIFILM Diosynth Biotechnology (U.S.), Samsung Biologics (South Korea), Siegfried Holding AG (Switzerland), Aenova Group (Germany), WuXi Biologics (China), and Vetter Pharma International GmbH (Germany). Market Outlook The North America pharmaceutical contract development and manufacturing market is segmented by service type: pharmaceutical manufacturing services (including active pharmaceutical ingredient [API] and finished dosage form [FDF] services), drug development services, and biologics manufacturing services. In 2024, pharmaceutical manufacturing services are expected to capture the largest market share, primarily due to the need to lower manufacturing costs, accelerate time-to- market for new drugs, meet bulk production requirements, and the increasing demand for generic medications. By end-user, the generic pharmaceutical companies segment is forecasted to experience the highest growth rate, driven by increased competition in the generic drug market, which exerts pricing pressure, and the growing adoption of advanced technologies provided by contract development and manufacturing companies. Geographic Overview Page 1 of 2 Meticulous Research| sales@meticulousresearch.com

North America Pharmaceutical Contract Development and Manufacturing Market - 2024-2030 This report covers the U.S. and Canada, with the U.S. anticipated to hold the largest market share in 2024. The dominance of the U.S. is attributed to the presence of leading pharmaceutical companies, frequent drug shortages, and the financial strength of small and mid-sized pharmaceutical firms. Smaller companies are also making strides in cell and gene therapy production. For example, in May 2021, Catalent Inc. (U.S.) expanded its capabilities by acquiring Promethera s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS). This acquisition includes a 32,400-square-foot facility in Gosselies, Belgium, which will enable Catalent to expand its commercial-scale plasmid DNA (pDNA) manufacturing and support the growing pipeline for cell and gene therapies. Buy Now@ https://www.meticulousresearch.com/Checkout/86686296?utm_source=pdf&utm_medium=soc ial&utm_campaign=product&utm_content=24-09-2024 About Meticulous Research : Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth. Contact Us: Meticulous Research Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research Page 2 of 2 Meticulous Research| sales@meticulousresearch.com